TLDR:
- Capstan Therapeutics, a biotechnology company, raised $175M in Series B funding to advance its lead in vivo CAR-T candidate and further develop its tLNP pipeline.
- The funding round was led by RA Capital Management and included new investors Forbion, Johnson & Johnson Innovation, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, and existing investors.
Capstan Therapeutics, based in San Diego, CA, specializes in advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles. The company’s lead candidate, CPTX2309, aims to reach early clinical proof-of-concept in autoimmune disorders. Nanna Luneborg, Ph.D., MBA, from Forbion, will join the company’s Board of Directors.
Capstan’s core platform technology, tLNP, has the potential to deliver transformative therapies for a variety of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. CEO Laura Shawver leads the company in its mission to develop targeted in vivo RNA technologies.
